Abstract
A comparison was made of the therapeutic efficiency and tolerance of rifampin-based regimens and that of the standard triple-drug combination in the treatment of 92 newly diagnosed cases of pulmonary tuberculosis. The three drug regimens investigated were: A, rifampin-INH; B, rifampin-INH-streptomycin; and C, INH-PAS-streptomycin. Therapeutic progress was measured in terms of sputum conversion on culture and microscopy. The rifampin combinations produced a somewhat earlier sputum conversion. With regimens containing this potent antibiotic the phenomenon of microscopically-positive but culture-negative specimens was more frequently observed. The tolerance exhibited to the rifampin regimens was far greater than that to the conventional triple-drug combination. Nevertheless, periodic laboratory examinations are essential during rifampin therapy for safe utilization of the drug. An incidental finding of this study was the increase in primary resistance to streptomycin particularly among recent immigrants to Canada.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Armstrong A. R. The prevalence in Canada of drug-resistant tubercle bacilli in newly discovered untreated patients with tuberculosis. Can Med Assoc J. 1966 Feb 26;94(9):420–425. [PMC free article] [PubMed] [Google Scholar]
- Clarke G. B., Cuthbert J., Cuthbert R. J., Lees A. W. Isoniazid plus rifampicin in the initial treatment of pulmonary tuberculosis. Br J Dis Chest. 1972 Oct;66(4):268–271. doi: 10.1016/0007-0971(72)90046-0. [DOI] [PubMed] [Google Scholar]
- Constans P., Baron A., Parrot R., Coury C. A study of 200 cases of active, recent pulmonary tuberculosis treated with rifampin-isoniazid. A follow-up history of one and one-half to three years. Chest. 1972 Jun;61(6):539–549. doi: 10.1378/chest.61.6_supplement.539. [DOI] [PubMed] [Google Scholar]
- Grumbach F., Canetti G., Le Lirzin M. Caractère durable de la stérilisation de la tuberculose expérimentale de la souris par l'association rifampicine-isoniazide: épreuve de la cortisone. Rev Tuberc Pneumol (Paris) 1970 Mar;34(2):312–319. [PubMed] [Google Scholar]
- Jeanes C. W., Jessamine A. G., Eidus L. Treatment of chronic drug-resistant pulmonary tuberculosis with rifampin and ethambutol. Can Med Assoc J. 1972 Apr 22;106(8):884–888. [PMC free article] [PubMed] [Google Scholar]
- Lees A. W., Allan G. W., Smith J., Tyrrell W. F., Fallon R. J. Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle. 1971 Sep;52(3):182–190. doi: 10.1016/0041-3879(71)90041-9. [DOI] [PubMed] [Google Scholar]
- Newman R., Doster B., Murray F. J., Ferebee S. Rifampin in initial treatment of pulmonary tuberculosis. A U.S. Public Health Service tuberculosis therapy trial. Am Rev Respir Dis. 1971 Apr;103(4):461–476. doi: 10.1164/arrd.1971.103.4.461. [DOI] [PubMed] [Google Scholar]
- Proust A. J. The Australian rifampicin trial. Med J Aust. 1971 Jul 10;2(2):85–94. [PubMed] [Google Scholar]
- Raleigh J. W. Clinical notes on rifampin--a new antituberculosis drug. Clin Notes Respir Dis. 1972 Summer;11(1):3–11. [PubMed] [Google Scholar]